List of Excipients in Branded Drug FENOPROFEN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	BROWN IRON OXIDE
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	CROSPOVIDONE
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	GELATIN
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	MAGNESIUM STEARATE
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	SODIUM LAURYL SULFATE
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	TALC
Belcher PharmaceuticalsLLC	FENOPROFEN	fenoprofen calcium	62250-691	TITANIUM DIOXIDE

Generic Drugs Containing FENOPROFEN

Company	Ingredient	NDC	Excipient
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	AMMONIA
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	CROSPOVIDONE
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FD&C BLUE NO. 1
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FD&C RED NO. 40
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FD&C YELLOW NO. 6
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	FERRIC OXIDE YELLOW
Rising Pharma Holdings Inc	fenoprofen calcium	16571-688	GELATIN

What are the Most Frequently-Used Excipients in FENOPROFEN?

# Of NDCs	Excipient

Fenoprofen Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Fenoprofen is an older nonsteroidal anti-inflammatory drug (NSAID) marketed in the United States as fenoprofen calcium, primarily in oral capsules. Its active-ingredient and basic dosage-form patent barriers are no longer commercially significant. The opportunity is therefore formulation-led: reliable low-cost generic supply, improved swallowability, suspension development, modified release, and differentiated packaging or dosing formats.

The strongest near-term strategy is a conventional immediate-release capsule or tablet using a robust dry-blend or wet-granulation process. Liquid, orally disintegrating, and modified-release products offer greater differentiation but carry higher development, stability, bioequivalence, and regulatory risk.

What is fenoprofen and which dosage forms are commercially relevant?

Fenoprofen is an NSAID used for symptomatic treatment of rheumatoid arthritis and osteoarthritis. In the United States, the approved product is fenoprofen calcium, commonly identified by the brand Nalfon. The FDA labeling describes oral capsule strengths of 300 mg and 600 mg fenoprofen calcium equivalents.[1]

Attribute	Fenoprofen
Active ingredient	Fenoprofen calcium
Therapeutic class	NSAID
Approved U.S. route	Oral
Primary approved dosage form	Immediate-release capsule
Common strengths	300 mg and 600 mg
Key indications	Rheumatoid arthritis, osteoarthritis
Regulatory pathway for generic products	Abbreviated New Drug Application, or ANDA
Biologic or biosimilar relevance	None
Main formulation issue	High-dose oral delivery with acceptable dissolution and tolerability
Commercial position	Mature, low-volume generic or niche branded product

Fenoprofen is not a biologic and has no biosimilar pathway. Commercial competition is expected to come from generic manufacturers and reformulation companies rather than biosimilar developers.

What excipients are suitable for fenoprofen capsules and tablets?

The preferred excipient system depends on the dosage form, manufacturing process, target disintegration time, and dissolution profile. Because fenoprofen products must deliver a relatively high dose, the formulation should minimize unnecessary excipient load.

Immediate-release hard capsules

A conventional capsule can use:

• Microcrystalline cellulose as a filler and dry-granulation aid
• Lactose monohydrate or anhydrous lactose as a diluent
• Povidone or pregelatinized starch as a binder
• Croscarmellose sodium or sodium starch glycolate as a superdisintegrant
• Colloidal silicon dioxide as a glidant
• Magnesium stearate or sodium stearyl fumarate as a lubricant
• Hard gelatin or hydroxypropyl methylcellulose capsule shells
• Titanium dioxide and approved colorants, where permitted

A practical starting platform is microcrystalline cellulose with a superdisintegrant, colloidal silicon dioxide, and a low lubricant concentration. This approach reduces formulation complexity and is compatible with direct compression or dry granulation.

Formulation objective	Candidate excipient	Primary function	Main risk
Increase bulk	Microcrystalline cellulose	Diluent, compressibility	Excessive tablet weight
Improve flow	Colloidal silicon dioxide	Glidant	Overuse can affect compaction
Accelerate disintegration	Croscarmellose sodium	Superdisintegrant	Sensitivity to over-compression
Bind granules	Povidone	Binder	Slower dissolution at high levels
Lubricate	Magnesium stearate	Lubricant	Hydrophobic coating and delayed release
Improve compactability	Pregelatinized starch	Binder/disintegrant	Moisture-related variability
Replace gelatin	HPMC capsule shell	Vegetarian capsule	Different moisture behavior

The key development variable is not simply disintegration. Fenoprofen calcium must meet dissolution requirements across the relevant pH range, and the formulation must remain bioequivalent to the reference product. Excess magnesium stearate, excessive granulation liquid, or high compression force can slow release.

Immediate-release tablets

Tablets may reduce packaging cost and improve manufacturing efficiency, but they can create a larger swallowing burden at 600 mg. A bilayer or scored tablet could support dose flexibility, although the added complexity is difficult to justify unless a clear clinical or commercial need exists.

For a conventional tablet, a dry-granulated formulation is commercially attractive because it limits water exposure and supports high-throughput production. Wet granulation can improve content uniformity and flow when the active blend has poor flow, but it adds drying and process-control requirements.

A development program should compare:

1. Direct compression.
2. Roller compaction followed by compression.
3. Wet granulation followed by compression.

The preferred process should be selected using blend uniformity, tablet tensile strength, friability, disintegration, dissolution, and stability data. The formulation should also be tested after exposure to elevated humidity because capsule and tablet performance can change with moisture uptake.

What excipient strategy is best for fenoprofen calcium?

A low-risk commercial formulation should prioritize immediate release, low unit cost, and broad supplier availability.

Recommended first-line platform

A suitable initial platform is:

• Fenoprofen calcium
• Microcrystalline cellulose
• Croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate
• Hard gelatin or HPMC capsule shell

This composition is compatible with standard generic manufacturing equipment and avoids dependence on specialized excipients. The final formula must be established through compatibility, dissolution, and stability studies rather than copied from a theoretical composition.

Excipient compatibility priorities

Fenoprofen calcium should be evaluated against:

• Lactose, because reducing sugars can create compatibility concerns with amine-containing drugs, although fenoprofen itself does not contain a primary amine
• Alkaline excipients, which may alter the ionization environment and dissolution behavior
• High-moisture excipients, which can affect physical stability
• Lubricants, particularly magnesium stearate, because surface coating can delay wetting
• Film-coating systems, where coating weight can affect disintegration and dissolution

Compatibility studies should use binary mixtures and the proposed final formulation. Recommended analytical tools include differential scanning calorimetry, thermogravimetric analysis, infrared spectroscopy, powder X-ray diffraction where solid-state changes are suspected, and chromatographic impurity testing.

What formulations are protected by fenoprofen patents?

The commercial patent risk for fenoprofen is low because the product was introduced decades ago and is not dependent on a recent active-ingredient patent.

Protection category	Current commercial relevance
Fenoprofen active-ingredient patents	Historical; expected to be expired
Fenoprofen calcium composition patents	Historical; expected to be expired
Original immediate-release capsule patents	Historical; expected to be expired
Method-of-use patents for arthritis	Historical or clinically narrow
Modern formulation patents	Potentially relevant only to newly developed products
Manufacturing-process patents	Possible for a new process, but unlikely to block conventional generic entry
FDA three-year exclusivity	No current basis identified for the established product
Five-year NCE exclusivity	Expired
Orphan exclusivity	Not applicable based on the established indications

The relevant current check is the FDA Orange Book and associated FDA product databases. A current applicant should verify the listed reference product, therapeutic equivalence codes, and any remaining patent or exclusivity entries before filing. The Orange Book is the controlling commercial reference for listed patents and exclusivity tied to approved FDA products.[2]

When does fenoprofen lose exclusivity?

Fenoprofen’s original regulatory and patent exclusivity expired long ago. No meaningful new chemical entity exclusivity remains for the established product. Generic entry is therefore governed primarily by ANDA requirements, product availability, manufacturing economics, and any current listed patents associated with a specific approved product.

A generic applicant would typically rely on:

• Paragraph I certification if no relevant patent is listed
• Paragraph III certification if a listed patent remains in force and the applicant accepts delayed approval
• Paragraph IV certification if the applicant challenges a listed patent
• Section viii statement for a method-of-use patent where the proposed label omits the protected use

For a mature fenoprofen product, a Paragraph IV campaign appears less commercially compelling than a standard ANDA unless a newly listed formulation or use patent creates a meaningful barrier.

Are there Paragraph IV challenges to fenoprofen?

No prominent current Paragraph IV litigation is associated with the established fenoprofen calcium product in the major publicly visible federal pharmaceutical litigation record. The drug’s age and limited market size reduce the incentive for a high-cost patent challenge.

The more likely generic-entry pathway is a conventional ANDA supported by bioequivalence to the reference product. A Paragraph IV strategy would make sense only if:

• The reference product has a currently listed patent.
• The product has enough sales to justify litigation expenditure.
• The proposed product offers a significant manufacturing or commercial advantage.
• The patent covers a commercially necessary formulation rather than an easily avoided feature.

Patent litigation risk should be assessed separately for the active ingredient, formulation, method of use, and manufacturing process. Those categories have different design-around options.

What FDA regulatory status applies to fenoprofen?

Fenoprofen is an FDA-approved prescription NSAID. FDA labeling contains class warnings relevant to gastrointestinal bleeding, cardiovascular thrombotic events, renal toxicity, hypertension, heart failure, and hypersensitivity reactions.[1]

A new oral fenoprofen product would generally require an ANDA if it is pharmaceutically equivalent and bioequivalent to an approved reference product. A materially different dosage form, strength, route, or clinical use could require a 505(b)(2) application rather than an ANDA.

Product concept	Likely U.S. pathway
Same-strength immediate-release capsule	ANDA
Same formulation with different capsule shell	Usually ANDA if equivalence is demonstrated
Tablet replacing capsule	Potentially ANDA or 505(b)(2), depending on reference-product standards
Oral suspension	Likely 505(b)(2) unless an appropriate reference and equivalence pathway is available
Modified-release product	505(b)(2) or complex ANDA, depending on the product and FDA requirements
New indication	505(b)(2) or supplemental NDA
Fixed-dose combination	505(b)(2) or NDA, depending on the combination

The FDA Inactive Ingredient Database can support excipient selection by identifying inactive ingredients previously used in approved products and their maximum potency levels.[3] It does not replace formulation-specific safety, quality, or compatibility testing.

What commercial opportunities exist for fenoprofen reformulation?

The commercial opportunity is niche rather than mass-market. Fenoprofen is unlikely to support a premium product solely through a new capsule shell or minor excipient substitution. Stronger opportunities involve a clear dosing, adherence, supply, or administration advantage.

1. Reliable generic supply

The most practical opportunity is a low-cost ANDA product that addresses supply continuity. Mature NSAIDs can experience intermittent availability when few manufacturers serve the market. A manufacturer with validated API sourcing, dual-site production, and reliable packaging could compete even in a low-volume market.

Key commercial requirements include:

• Competitive cost of goods
• Stable fenoprofen calcium API supply
• Standard capsule equipment
• Low-cost blister or bottle packaging
• Adequate wholesaler and group-purchasing access
• Consistent FDA compliance history

2. HPMC capsule or lower-gelatin product

An HPMC capsule could appeal to customers seeking vegetarian or non-animal-derived dosage forms. This is a modest differentiator, not a strong exclusivity platform. The shell must be evaluated for moisture transmission, brittleness, dissolution, and compatibility with the fill.

3. Oral suspension

An oral suspension could target patients unable to swallow capsules, including older adults and patients with dysphagia. The technical barriers are material:

• Fenoprofen calcium may require particle-size control
• Sedimentation and redispersibility must be controlled
• Taste masking may be necessary
• Preservative effectiveness must be demonstrated
• Container-closure compatibility must be established
• Dose uniformity must remain acceptable throughout shelf life

Suspensions can support a 505(b)(2) strategy but require more regulatory work than a standard capsule.

4. Modified-release delivery

Modified release could reduce dosing frequency, but the opportunity is uncertain. Fenoprofen’s established clinical use does not automatically demonstrate demand for once-daily delivery. A modified-release product would require pharmacokinetic and clinical justification, and NSAID exposure may raise safety concerns if peak and trough concentrations change materially.

Potential technologies include:

• Hydrophilic matrix tablets using hypromellose
• Insoluble matrix systems
• Multiparticulate beads
• Coated pellets in capsules

A modified-release product should not be pursued without a defined target product profile, evidence of adherence value, and a regulatory route that supports the proposed claims.

5. Orally disintegrating tablet

An orally disintegrating tablet could address swallowing difficulty but faces a dose-load problem at 300 mg or 600 mg. It would likely require multiple units, taste masking, or a high-load formulation. That may produce a large tablet or a less acceptable mouthfeel.

6. Combination products

Combining fenoprofen with a gastroprotective agent or another analgesic could create a differentiated product, but clinical, regulatory, and safety requirements would be substantial. A combination NSAID product also raises concerns about duplicate analgesic therapy and gastrointestinal or renal risk. This is a higher-risk opportunity than a conventional generic.

How does fenoprofen compare with competing NSAIDs?

Fenoprofen competes with inexpensive NSAIDs that have larger prescriber familiarity and broader generic availability. Ibuprofen, naproxen, diclofenac, and meloxicam generally have stronger commercial scale or more established once-daily positioning.

Drug	Commercial advantage over fenoprofen	Formulation implication
Ibuprofen	Very broad consumer and prescription use	Strong price competition
Naproxen	Longer dosing interval and extensive generic availability	More difficult to justify fenoprofen reformulation
Diclofenac	Multiple dosage forms and topical products	Differentiation through route and delivery
Meloxicam	Once-daily dosing	Fenoprofen modified release would need a clear benefit
Fenoprofen	Established indication and legacy physician familiarity	Best positioned as a reliable niche generic

Fenoprofen’s commercial weakness is the absence of a clear modern convenience advantage. Its strongest position is as an alternative oral NSAID for patients already treated successfully with the molecule or where supply and formulary economics create an opening.

What manufacturing and intellectual-property barriers exist?

The active ingredient itself is unlikely to create a meaningful patent barrier. Manufacturing barriers are more practical:

• API crystallinity and particle-size consistency
• Blend uniformity at high drug loading
• Lubrication control
• Dissolution reproducibility
• Capsule-fill weight variation
• Stability under humidity stress
• Reliable sourcing of fenoprofen calcium
• Validation of cleaning and cross-contamination controls

A new manufacturing process could potentially receive patent protection if it produces a measurable improvement in purity, yield, particle engineering, dissolution, or stability. Such protection would generally be narrow and would not block all conventional fenoprofen products.

Geographic coverage is also important. U.S. approval does not establish European, Canadian, Japanese, or other-market approval. Excipients must comply with the applicable pharmacopoeia and local regulatory standards. A global product should use excipients with broad compendial acceptance and established supplier documentation.

What licensing deals and partnering opportunities exist?

Fenoprofen is unlikely to attract a large originator-style licensing transaction. Commercial partnering is more likely to involve:

• Regional commercialization rights
• Contract manufacturing
• API supply agreements
• Private-label generic distribution
• 505(b)(2) development partnerships
• Reformulation licensing
• Hospital or specialty-pharmacy supply contracts

A licensing transaction would need to justify the cost of regulatory filing, stability studies, packaging, inventory, and pharmacovigilance. For the conventional capsule, manufacturing or distribution rights are more realistic than licensing a high-value formulation patent.

How strong is the fenoprofen patent estate?

The established fenoprofen patent estate is weak from a blocking perspective. The molecule and original product are old, and conventional immediate-release formulations are readily designable around. Any commercial strength would come from:

• A newly patented delivery system
• A validated low-impurity manufacturing process
• A protected suspension or modified-release system
• A formulation with demonstrated clinical or adherence benefit
• Regulatory exclusivity attached to a new indication or dosage form

A new patent should not rely solely on listing common excipients. Patent value would be stronger where the formulation has a defined composition range linked to a reproducible dissolution profile, stability improvement, reduced variability, or clinically meaningful performance.

What generic launch scenarios exist for fenoprofen?

Low-cost conventional generic

This is the most credible scenario. The applicant uses a standard immediate-release capsule, files an ANDA, and competes primarily on supply reliability and price.

Niche dosage-form launch

A 505(b)(2) oral liquid, HPMC capsule, or orally disintegrating product could command limited differentiation. The opportunity depends on demonstrated patient need and payer acceptance.

Premium modified-release product

This has the highest development risk. The product would need a convincing pharmacokinetic, clinical, and economic rationale against once-daily competing NSAIDs.

Regional or institutional supply

A manufacturer could focus on hospitals, long-term-care facilities, or government procurement. This model may work with modest volumes if manufacturing costs and supply reliability are controlled.

What revenue exposure is associated with fenoprofen?

Fenoprofen is a small-market product relative to leading NSAIDs. Its revenue exposure is therefore more sensitive to:

• Product discontinuations
• API shortages
• Contract-manufacturing failures
• Single-supplier dependence
• Wholesaler stocking decisions
• Formulary removal
• Low manufacturing scale

Public revenue estimates should be treated carefully because fenoprofen sales may be distributed among generic suppliers, private-label products, and limited branded channels. The commercial case should rely on current prescription volume, ASP, competitor count, shortage history, and payer concentration rather than historical brand sales.

Key Takeaways

• Fenoprofen is an old oral NSAID marketed primarily as fenoprofen calcium.
• Original molecule and product exclusivity are no longer the main commercial barriers.
• A conventional immediate-release capsule is the lowest-risk development opportunity.
• Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and controlled magnesium stearate levels provide a practical starting platform.
• The main technical risks are dissolution, high-dose capsule loading, blend uniformity, lubrication, and moisture-related stability.
• A standard generic would normally use an ANDA if an appropriate reference product is available.
• No major current Paragraph IV opportunity is apparent for the established product.
• Oral suspension and modified-release products offer differentiation but likely require a 505(b)(2) strategy or complex ANDA development.
• Commercial value is more likely to come from supply reliability, niche distribution, or patient-friendly delivery than from premium pricing.
• New patent value would need to arise from a specific formulation, manufacturing process, or clinically relevant delivery improvement.

FAQs

Is fenoprofen calcium the same as fenoprofen?

Fenoprofen calcium is the calcium salt used in the approved oral product. Label dosing is expressed as fenoprofen calcium rather than the free acid.

Can fenoprofen be formulated as an oral liquid?

Yes, but an oral liquid would require suspension stability, redispersibility, dose uniformity, taste, preservative, and container-closure development. It would be more complex than a conventional capsule.

Does fenoprofen have biosimilar competition?

No. Fenoprofen is a small-molecule NSAID. Competition occurs through generic drug applications, not biosimilar applications.

Which excipient is most likely to delay fenoprofen dissolution?

Excessive magnesium stearate, high hydrophobic lubricant exposure, over-compression, and dense granulation can delay wetting or disintegration. The effect must be confirmed through formulation-specific dissolution testing.

Is fenoprofen a strong candidate for a modified-release product?

It is technically feasible but commercially uncertain. The product would need a clear dosing or adherence advantage over widely available once-daily NSAIDs such as meloxicam and longer-acting naproxen formulations.

References

1. U.S. Food and Drug Administration. (2023). Nalfon (fenoprofen calcium) capsules: Prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.
3. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
4. National Center for Biotechnology Information. (2024). PubChem compound summary: Fenoprofen calcium. PubChem.
5. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.